Chemotherapie des hormonrefraktären Prostatakarzinoms

Zusammenfassung

Die lange Zeit herrschende Skepsis bezüglich einer Chemotherapie des hormonrefraktären Prostatakarzinoms (HRPC) ist einer Welle von Enthusiasmus gewichen. In Phase-II-Studien mit taxanhaltigen Kombinationstherapien konnten zum Teil hohe Ansprechraten erzielt werden. Von einer Resistenz des HRPC gegenüber Chemotherapie kann also nicht mehr länger die Rede sein. Es bleibt abzuwarten, inwieweit die Kombinationen auch einen Überlebensvorteil haben. Dies wird derzeit in Phase-III-Studien überprüft. An eine palliative Chemotherapie sollte bei Patienten mit HRPC vor allem dann gedacht werden, wenn die initiale Hormontherapie nur kurz gewirkt hat und bereits mehrere Hormontherapien durchlaufen wurden [39]. Die Chemotherapie ist jedoch bislang noch keine Standardtherapie des HRPC. Patienten sollten daher möglichst in klinische Studien eingebracht werden.

Abstract

The scepticism dominating the chemotherapy of the hormone-refractory prostate cancer (HRPC) has been replaced by a wave of enthusiasm. Phase II studies with taxane-containing combination therapies could achieve high response rate in some cases, and HRPC can not longer be deemed resistant to chemotherapy. It remains to be seen whether the combinations offer a survival advantage. This will be tested in phase III studies. Palliative chemotherapy should be considered in patients with HRPC if the initial hormone therapy was effective for a short time only and after several hormone therapies have been completed. Since chemotherapy is not yet an established standard therapy of HRPC, patients should be, if possible, included in clinical studies.

Hormonrefraktäres Prostatakarzinom - Chemotherapie - Kombinationstherapie

Hormone-refractory prostate carcinoma - chemotherapy - combination therapy

Literatur

• 1 Mahler C, Denis L. Hormone refractory disease.  Semin Surg Oncol. 1995;  11 77
• 2 Fowler J E, Whitmore W F Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone.  J Urol. 1981;  126 372
• 3 Taylor C D, Elson P, Trump D L. Importance of continued testicular suppression in hormone-refractory prostate cancer.  J Clin Onol. 1993;  11 2167
• 4 Hussein M, Wolf M, Marshall E. et al . Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.  Clin Oncol. 1994;  12 1868
• 5 Kelly W K, Scher H I. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.  J Urol. 1993;  149 607
• 6 Scher H I, Steineck G, Kelly W K. Hormone-refractory (D3) prostate cancer: refining the concept.  Urology. 1995;  46 142
• 7 Scher H I, Mazumdar M, Kelly W K. Clinical trials in relapsed prostate cancer. Definig the target.  J Natl Cancer Inst.. 1996;  88 1623
• 8 Wolff J, Altwein J E. Prostatakarzinom - Grundlagen und Therapie. Berlin: Springer-Verlag 2003
• 9 Knox J J, Moore M J. Treatment of hormone refractory prostate cancer.  Semin Urol Oncol. 2001;  19 202-211
• 10 Scher H I, Fossa S. Prostate cancer in the era of prostate specific antigen.  Curr Opin Oncol. 1995;  7 281
• 11 Vogelzang N J. One hundred thirteen men with hormone-refractory prostate cancer died today.  J Clin Oncol. 1996;  14 1753
• 12 Eisenberger M A, Abrams J S. Chemotherapy for prostatic carcinoma.  Semin Urol. 1988;  6 303
• 13 Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer.  Cancer. 1993;  71 (suppl.3) 1098
• 14 Small E J, McMillan A, Meyer M. et al . Serum prostate antigene decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression free survival, pain end points and survival.  J Clin Oncol. 2001;  19 1304
• 15 Benson R, Hartley-Asp B. Mechanisms of action and clinical uses of estramustine.  Cancer Invest. 1990;  8 375
• 16 Tannock I F, Osoba D, Stockler M R. et al . Chemotherapy with mitoxantrone lus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points.  J Clin Oncol. 1996;  14/6 1756-1764
• 17 Kantoff P W, Halabi S, Conaway M. et al . Hydrocortison with or withaout mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B9182 study.  J Clin Oncol. 1999;  17/8 2506-2513
• 18 Johannsen M, Wilke K, Schnorr D, Loenig S A. Taxane in der Chemotherapie des hormonrefraktären Prostatakarzinoms.  Der Urologe. 2004;  43 160-167
• 19 Roth B J, Yeap B Y, Wilding G. et al . Taxol in advanced, hormone-refractory carcinoma of the prostate. A phae II trial of the Eastern Cooperative Oncology Group.  Cancer. 1993;  72/8 2457-2460
• 20 Trivedi C, Redman B, Flaherty L E. et al . Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.  Cancer. 2000;  89/2 431-436
• 21 Scholz M C, Guess B, Barrios F, Srum S, Leibowitz R. Low-dose, single agent weekly docetaxel is effective and well toleratet in elderly men with prostate cancer.  Proc Am Soc Clin Oncol. 2001;  20 173b
• 22 Casciano R, Petrylak D, Amaya K. et al . Systematic review of chemotherapy efficacy from controlled clinical trials in hormone-refractory prostate cancer patients.  Proc Am Soc Clin Oncol. 2001;  20 169
• 23 Hass N, Roth B, Garay C. et al . Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.  Urology. 2001;  58 159-164
• 24 Vaughn D J, Brown A, Harker W G. Phase II evaluation of weekly paclitaxel and estramustine phosphate in androgen independent prostate cancer.  Proc ASCO. 2003;  22 Abstract 1615
• 25 Kuzel T M, Kies M S, Wu N. et al . Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormonerefractory prostate cancer.  Cancer Invest. 2002;  20/5 - 6 634-643
• 26 Hudes G R, Nathan F, Khater C. et al . Phase II trail of 96 hour pclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.  J Clin Oncol. 1997;  15/9 3156-3163
• 27 Copur M S, Ledakis P, Lynch J. et al . Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.  Semin Oncol. 2001;  28 16
• 28 Petrylak D P, Macarthur R, O'Connor J. et al . Phase I/II studies of docetaxel combined with estramustine in men with hormone refractory prostate cancer.  Semin Oncol. 1999;  26 28
• 29 Savarese D M, Halabi S, Hars V. et al . Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone refractory cancer. A final report of CALGB 9780.  J Clin Oncol. 2001;  19 2509-2
• 30 Sinibaldi V J, Carducci M A, Moore Cooper S. et al . Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.  Cancer. 2002;  94 1457
• 31 Miller K, Steiner U, Machtens S. et al . Combination chemotherapy with weekly docetaxel and intermittent estramustine in patients with hormone refractory prostate cancer (HRPC): A multicenter phase II study.  Proc Am Soc Clin Oncol. 2003;  22 (abstr) 1660
• 32 Heidenreich A, Knobloch R von, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.  Eur Urol. 2001;  39 121-130
• 33 Petrylak D P, Macarthur R B, O'Connor J. et al . Phase I trial of docetaxel with estramustine in androgen independent prostate cancer.  J Clin Oncol. 1999;  17/3 958-967
• 34 Petrylak D P, Shelton G B, England Owen C. et al . Response and preliminary survival results of a phase II study of docetaxel and estramustine in patients with androgen independent prostate cancer (AIPCA).  Proc Am Soc Clin Oncol. 2000;  19 334a
• 35 Oudard S, Banu E, Voog E. et al . Results of a phase II randomized trial of docetaxel, estramustine and prednisone- two schedules- verus mitoxantrone and prednisone in patients with hormone refractory prostate cancer.  Eur Urol. 2003;  2 (suppl 1) 189-Abstract 746
• 36 Sitki C opur , Ledakis P, Lynch J. et al . Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.  Semin Oncol. 2001;  28/4 (Suppl 15) 16-21
• 37 Meluch A A, Greco F A, Morrissey L H. et al . Weekly paclitaxel, estramustin posphate and oral etoposide in the treatment of hormone-refractory prostate carcinoma.  Cancer. 2003;  98/10 2192-2198
• 38 Smith D C, Chay C H, Dunn R L. et al . Phase II trail of paclitaxel, estramustine, etoposide and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.  Cancer. 2003;  98/2 269-276
• 39 Kelly W K, Curley T, Slovin S. et al . Paclitaxel,estramustine phosphate and carboplatin in patients with advanced prostate cancer.  J Clin Oncol. 2001;  19/1 44-53
• 40 Savarese D M, Halabi S, Hars V. et al . Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780.  J Clin Oncol. 2001;  19/9 2509-2516
• 41 Veldhiuzen P J Van, Reed G, Aggarwal A. et al . Docetaxel and ketoconazole in advanced hormone refractory prostate carcinoma. A Phase I and pharmokinetic study.  Cancer. 2003;  98/9 1855-1862
• 42 Beer T M, Eilers K M, Garzotto M. et al . Weekly high dose calcitriol and docetaxel in metastatic androgen independent prostate cancer.  J Clin Oncol. 2003;  12/9 123-128
• 43 Koletsky A J, Guerra M L, Kronish L. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naïve patients with hormone refractory prostate cancer.  Cancer J. 2003;  9/4 286-292
• 44 Pruitt-Scott D E, Ryan C W, Stadler W M, Vogelzang N J. Exisulind plus docetaxel for hormone refractory prostate cancer.  Proc Am Soc Clin Oncol. 2002;  21 161b
• 45 Dahut W L, Arlen P M, Gulley J. et al . A radomized phase II trial of docetaxel plus thalidomide in androgen independent prostate cancer.  Proc Am Soc Clin Oncol. 2002;  21 183b
• 46 Wolff J M. Docetaxel beim hormonrefraktären Prostatakarzinom.  Onkologie. 2003;  26 (Suppl 7) 37-40